References
- Aldecott KW (2003). XRCC1 and DNA strand break repair. DNA Repair (Amst), 2, 955-69. https://doi.org/10.1016/S1568-7864(03)00118-6
- Alderton GK, Galbiati L, Griffith E, et al (2006). Regulation of mitotic entry by microcephalin and its overlap with ATR signalling. Nat Cell Biol, 8, 725-33, . https://doi.org/10.1038/ncb1431
- Arthur TJ, Rachel IV, Stefan EP, et al (2012). Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol, 7, 42. https://doi.org/10.1186/1746-1596-7-42
- Balmana J, Domchek SM, Tutt A, Garber JE (2011). Stumbling blocks on the path to personalized medicine in breast cancer, the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov, 1, 29-34. https://doi.org/10.1158/2159-8274.CD-11-0048
- Basu B, Sandhu SK, de Bono JS (2012). PARP inhibitors, mechanism of action and their potential role in the prevention and treatment of cancer. Drugs, 72, 1579-90, . https://doi.org/10.2165/11635510-000000000-00000
- Bhattacharya N, Mukherjee N, Singh RK, et al (2012). Frequent Alterations of MCPH1 and ATM are Associated with Primary Breast Carcinoma, Clinical and Prognostic Implications. Ann Surg Oncol, 2, 12-45.
- Biesalski HK, Bueno de Mesquita B, Chesson A, et al (1998). European Consensus Statement on Lung Cancer, risk factors and prevention. Lung Cancer Panel. CA Cancer J Clin, 48, 167-76; discussion 164-6. https://doi.org/10.3322/canjclin.48.3.167
- Branzei D, Foiani M (2011). Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol, 11, 208-19.
- Bruning-Richardson A, Bond J, Alsiary R, et al (2011) ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. Br J Cancer, 104, 1602-10. https://doi.org/10.1038/bjc.2011.117
- Cao JY, Liu L, Chen SP, et al (2010). Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Mol Cancer, 9, 237. https://doi.org/10.1186/1476-4598-9-237
- Carter SL, Eklund AC, Kohane IS, et al (2006). A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet, 38, 1043-8. https://doi.org/10.1038/ng1861
- Chaplet M, Rai R, Jackson-Bernitsas D, et al (2006). BRIT1/MCPH1, a guardian of genome and an enemy of tumors. Cell Cycle, 5, 2579-83.. https://doi.org/10.4161/cc.5.22.3471
- Dan Longo, Anthony Fauci, Dennis Kasper, et al (2011). Harrison's Principles of Internal Medicine (18th ed). McGraw-Hill, New York, "Chapter 89".
- Driscoll M, Jackson AP, Jeggo PA (2006). Microcephalin,a causal linkbetween impaired damage response signalling and microcephaly. Cell Cycle, 5, 2339-44. https://doi.org/10.4161/cc.5.20.3358
- Farmer H, McCabe N, Lord C J, et al (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917-21. https://doi.org/10.1038/nature03445
- Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008, GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
- Fossella F, Pereira JR, von Pawel J, et al (2003). Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer, The TAX 326 study group. Jf ClinOncol, 21, 3016-24, . https://doi.org/10.1200/JCO.2003.12.046
- Gavvovidis I, Rost I, Trimborn M, et al (2012). A novel MCPH1 isoform complements the defective chromosome condensation of human MCPH1-deficient cells. PLoS One, 7, e40387. https://doi.org/10.1371/journal.pone.0040387
- Giallongo C, Tibullo D, La Cava P, et al (2011). BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. Acta Haematol, 126, 205-10. https://doi.org/10.1159/000329911
- Giovino GA, Mirza SA, Samet JM, et al (2012). Tobacco use in 3 billion individuals from 16 countries, an analysisof nationally representative cross-sectionalhousehold surveys. Lancet, 380, 668-79. https://doi.org/10.1016/S0140-6736(12)61085-X
- Goldberg M, Stucki M, Falck J, et al (2003). MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature, 421, 952-6. https://doi.org/10.1038/nature01445
- He J, Chen WQ (2013). Chinese Cancer Registry Annual Report In 2012. Military Medical Science Press, Beijing, China, C33-4.
- Hosseini MM, Tonekaboni SH, Papari E, et al (2012). A novel mutation in MCPH1 gene in an Iranian family with primary microcephaly. J Pak Med Assoc, 62, 1244-7.
- Hu RZ, Song FZ, Yuan CF, et al (2012). Effect of over-expression of BRIT1 gene on apoptosis of cervical cancer HeLa cells. Chin J Biologicals, 25, 429-32.
- Jo YH, Kim HO, Lee J, et al (2013). MCPH1 protein expression and polymorphisms are associated with risk of breast cancer. Gene, 517, 184-90. https://doi.org/10.1016/j.gene.2012.12.088
- Liang Y, Gao H, Lin SY, et al (2010). MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet, 6, e1000826. https://doi.org/10.1371/journal.pgen.1000826
- Lin SY, Rai R, Li K, Xu ZX, Elledge SJ (2005). BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci U S A, 102, 15105-9, . https://doi.org/10.1073/pnas.0507722102
- Lin SY, Rai R, Li K, et al (2005). BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1- Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci U S A, 102, 15105-9. https://doi.org/10.1073/pnas.0507722102
- Lou Z, Minter-Dykhouse K, Wu X, Chen J (2003). MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways. Nature, 421, 957-61, . https://doi.org/10.1038/nature01447
- Lu C, Onn A, Vaporciyan AA, et al (2010). Holland-Frei Cancer Medicine (8th ed.). People's Medical Publishing House, Beijing, China, pp78.
- Mavrou A, Tsangaris GT, Roma E, Kolialexi A (2008). The ATM gene and ataxia telangiectasia. Anticancer Res, 28, 401-5.
- McCabe N, Turner N C, Lord C J, et al (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res, 66, 8109-15. https://doi.org/10.1158/0008-5472.CAN-06-0140
- Peng G, Yim EK, Dai H, et al (2009). BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nat Cell Biol, 11, 865-72. https://doi.org/10.1038/ncb1895
- Qin LX (2002). Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol, 8, 769-76. https://doi.org/10.3748/wjg.v8.i5.769
- Rai R, Dai H, Multani AS, Li K, et al (2006). BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell, 10, 145-57. https://doi.org/10.1016/j.ccr.2006.07.002
- Rai R, Dai H, Multani AS, et al (2006). BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell, 10, 145-57. https://doi.org/10.1016/j.ccr.2006.07.002
- Richardson J, Shaaban AM, Kamal M, et al (2010). Reduced MCPH1 expression in breast cancer and response to chemotherapy. Breast Cancer Res, 12, p41.
- Richardson J, Shaaban AM, Kamal M, et al (2011).Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res Treat, 127, 639-48. https://doi.org/10.1007/s10549-010-1019-4
- Roy R, Chun J, Powell SN (2011). BRCA1 and BRCA2, different roles in a common pathway of genome protection. Nat Rev Cancer, 12, 68-78. https://doi.org/10.1038/nrc3181
- Shi L, Li M, Su B (2012). MCPH1/BRIT1 represses transcription of the human telomerase reverse transcriptase gene. Gene, 495, 1-9. https://doi.org/10.1016/j.gene.2011.12.053
- Shi L, Li M, Lin Q, Qi X, Su B (2013). Functional divergence of the brain-size regulating gene MCPH1 during primate evolution and the origin of humans. BMC Biol, 11, 62. https://doi.org/10.1186/1741-7007-11-62
- Stewart GS, Wang B, Bignell CR, et al (2003). MDC1 is a mediatorof the mammalian DNA damage checkpoint. Nature, 421, 961-6. https://doi.org/10.1038/nature01446
- Trimborn M, Schindler D, Neitzel H, Hirano T (2006). Misregulated chromosome condensation in MCPH1 primary microcephaly is mediated by condensin II. Cell Cycle, 5, 322-6. https://doi.org/10.4161/cc.5.3.2412
- Van't Veer LJ, Dai H, van de Vijver MJ, et al (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-6, . https://doi.org/10.1038/415530a
- Venkatesh T, Nagashri MN, Swamy SS, et al (2013). Primary microcephaly gene MCPH1 shows signatures of tumor suppressors and is regulated by miR-27a in oral squamous cell carcinoma. PLoS One, 8, e54643. https://doi.org/10.1371/journal.pone.0054643
- Vinay Kumar, Abul K Abbas, Nelson Fausto, et al (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier, Amsterdam, pp528-9.
- Xu X, Lee J, Stern DF (2004). Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1. J Biol Chem, 279, 34091-4. https://doi.org/10.1074/jbc.C400139200
- Yamashita D, Shintomi K, Ono T, et al (2011). MCPH1 regulates chromosome condensation and shaping as a composite modulator of condensin II. J Cell Biol, 194, 841-54. https://doi.org/10.1083/jcb.201106141
- Yang SZ, Lin FT, Lin WC (2008). MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep, 9, 907-15. https://doi.org/10.1038/embor.2008.128
- Zhang B, Wang E, Dai H, Hu R, et al (2013). BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer. Carcinogenesis First published online, June 1.
- Zhou ZW, Tapias A, Bruhn C, et al (2013). DNA damage response in microcephaly development of MCPH1 mouse model. DNA Repair (Amst), 12, 645-55. https://doi.org/10.1016/j.dnarep.2013.04.017
Cited by
- Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model vol.34, pp.33, 2015, https://doi.org/10.1038/onc.2014.367
- Overexpression of MCPH1 inhibits uncontrolled cell growth by promoting cell apoptosis and arresting the cell cycle in S and G2/M phase in lung cancer cells vol.11, pp.1, 2015, https://doi.org/10.3892/ol.2015.3857